Clinical trials: Psychiatric Disorder
Attention Deficit and Hyperactivity Disorder
A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)
A multicenter, open label, escalating dose study to assess the tolerability and the safety and to explore the efficacy and the pharmacokinetics of ND0801 in adult patients with attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT01174355
- Testing
- ND0801
- Where
- 2 sites in Israel
- Volunteers
- 40 people
- Sponsor
- NeuroDerm Ltd.
Alcohol Use Disorder (AUD), Substance Use Disorders
The Anchor Study: Digitally Delivered Intervention for Reducing Problematic Substance Use
This study aims to validate W-SUDs as a digitally-delivered substance use disorder program through a fully-powered randomized control trial that will test the comparative efficacy of the mobile-app based substance use disorder…
- Trial name
- NCT04925570
- Testing
- W-SUDs, Digitally-delivered Psychoeducation
- Where
- United States
- Volunteers
- 258 people
- Sponsor
- Woebot Health
Dementia, Alzheimer's Disease
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
- Trial name
- NCT00104273
- Testing
- Rasagiline
- Where
- 58 sites in United States, Australia and 2 more
- Volunteers
- 376 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Attention-Deficit/Hyperactivity Disorder
A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The objective of this study is to compare the safety and efficacy of five doses of ABT-089 (2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD and 40 mg BID) to placebo in adults with ADHD.
- Trial name
- NCT00391729
- Testing
- ABT-089
- Where
- 23 sites in United States
- Volunteers
- 221 people
- Sponsor
- Abbott
Schizophrenia
Exploratory Study of a Digital Therapeutics in People With Schizophrenia
CT-155 is a novel prescription digital therapeutic (PDT) being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI) using an interactive, software-based intervention to treat schizophrenia
- Trial name
- NCT05438160
- Testing
- Clinical Learning Study smartphone app (i.e., the study app)
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Click Therapeutics, Inc.
Generalized Anxiety Disorder (GAD)
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD.
- Trial name
- NCT06846320
- Testing
- ABBV-932, Antidepressant Therapy (ADT)
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- AbbVie
Substance Use Disorders
Automated Assessment Using Facial Coding
Transition-age youth (TAY) from ages 18-26 are vulnerable to substance substance use disorder (SUD). This developmental period, termed "emerging adulthood" includes leaving home, entering college or working for the first time…
- Trial name
- R44DA042640 (NCT03551886)
- Testing
- Advanced Emotion App, Basic Emotion App
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- Treatment Innovations
Schizophrenia
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
This is a study designed to evaluate the safety, tolerability, and PK of SEP-363856 and its metabolite SEP-363854 in male and female subjects with schizophrenia.
- Trial name
- SEP-363856 (NCT01994473)
- Testing
- SEP-363856, SEP-363856 Open Label
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Maximum Diagnostic Mass of [18Fluor]AZD4694
An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease
In this study different mass of the radioligand AZD4694 will be given to patients with Alzheimer's Disease and healthy volunteers to evaluate wich Mass of AZD4694 that gives the best opportunities for following disease progress…
- Trial name
- NCT01325402
- Testing
- [18Fluor]AZD4694
- Where
- 2 sites in Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
AL Amyloidosis
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
This is a global, multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who…
- Trial name
- PRONTO (NCT02632786)
- Testing
- NEOD001
- Where
- 40 sites in United States, Australia and 8 more
- Volunteers
- 129 people
- Sponsor
- Prothena Biosciences Ltd.
Anxiety, Stress
A Clinical Trial to Assess the Impact of an Alcohol Alternative Herbal Tincture on Signs of Stress Anxiety and Sleep Quality.
This is a virtual randomized placebo-controlled double-blind trial lasting eight weeks. The trial will assess the effects of a test product on improving sleep quality, promoting a sense of calm, and reducing feelings of stress…
- Trial name
- NCT06505694
- Testing
- Alcohol Alternative Herbal Tincture (Test Product)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Apothekary
Sleep Initiation and Maintenance Disorders
15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.
Subjects will be screened within 28 days, Simvastatin dose and single SB-649868 dose 10 and 7 days prior to repeat dosing respectively, 15 days SB-649868 repeat dosing with safety and cognition function tests.
- Trial name
- NCT00495729
- Testing
- SB-649868, Simvastatin
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00707980
- Testing
- Vortioxetine
- Where
- 92 sites in United States, Australia and 15 more
- Volunteers
- 836 people
- Sponsor
- Takeda
Insomnia, Insomnia Disorder
DAO DEFICIENCY SCREENING AMONG PATIENTS WITH INSOMNIA SYMPTOMS
Insomnia is prevalent in the global population. Diamino oxidase (DAO) is an enzyme that degrades histamine. When there is not enough DAO enzyme activity in the body, histamine accumulates and it can lead to symptoms in the…
- Trial name
- NCT06488027
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- AB Biotek
Alzheimer Disease
GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease
A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's…
- Trial name
- NCT00414622
- Testing
- DMXB-A
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- CoMentis
Tobacco Use Disorder
To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers
This study will assess the bioequivalence of the test product (Nicotine Prototype Mini lozenge 4 milligrams [mg]) to a commercial reference product (nicotine polacrilex mini lozenge 4mg) in healthy smokers under fasting…
- Trial name
- NCT03543137
- Testing
- Nicotine Prototype Mini lozenge, Nicorette Mini Lozenge
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.
- Trial name
- RENEW-MDD-1 (NCT07412756)
- Testing
- Brenipatide
- Where
- 181 sites in United States, Australia and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder
A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder
To evaluate the efficacy and safety of once a day ramelteon tablets for sublingual administration (TAK-375SL) in the maintenance treatment of bipolar 1 disorder.
- Trial name
- NCT01685151
- Testing
- Ramelteon SL (Dose 1), Ramelteon SL (Dose 2)
- Sponsor
- Takeda
Alzheimer Disease
Transcranial Pulse Stimulation (TPS) for Alzheimer's Disease (AD)
This is a prospective open comprehensive proof-of-principle pilot study.
- Trial name
- NCT04333329
- Testing
- NEUROLITH
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Storz Medical AG
Bipolar Depression, Bipolar I Disorder
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
X-CEED-OLE is a Phase 3, multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner in adult participants who successfully completed an antecendent Phase 3 azetukalner bipolar…
- Conditions
- Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder
- Trial name
- NCT07217860
- Testing
- Azetukalner
- Where
- 20 sites in United States
- Volunteers
- 400 people
- Sponsor
- Xenon Pharmaceuticals Inc.